Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT00889421) enrolled 3 participants in a single treatment group. The study was investigating a treatment for eye inflammation (uveitis), and was looking at several things: whether vision improved by a meaningful amount, whether participants could reduce their use of steroids or other immune-suppressing medicines, whether signs of inflammation in the eye settled down, and whether fluid build-up at the back of the eye (the macula) decreased. A secondary aim was to track any unwanted or unexpected health events that occurred during the study. The reported data shows that none of the 3 participants completed the trial — all 3 withdrew or were otherwise recorded as "not completed." Because no participants finished the study, no results were recorded for any of the primary outcome measures (vision improvement, steroid reduction, inflammation control, or fluid reduction), and no results were recorded for the secondary outcome measure tracking adverse events either. The data was not reported for any of these measures. It is not possible to draw any conclusions about the treatment from this trial, as the study did not reach completion and no outcome data was submitted. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a serious eye condition called autoimmune uveitis that is threatening your vision
- Your condition has not responded to standard steroid treatment (prednisone) and at least one other medication that suppresses the immune system, OR you have had to stop those medications because of side effects
Who may not be able to join:
- You have another serious health condition that could make it difficult or unsafe for you to take part in the trial
- You have previously used or are currently using a strong type of chemotherapy drug called an alkylating agent
- You are currently taking certain medications that affect how the body processes drugs, known as CYP3A4 inhibitors — these include some common antibiotics and antifungal medicines (confirm with trial site)
- You have used a type of medication called a TNF blocker within the 8 weeks before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Improvement by 2 or More Lines of Best-corrected Snellen Visual Acuity in at Least One Eye; Reduction in Dose of Systemic Corticosteroid or Other Immunosuppressive Therapy by at Least 50%; Control of Ocular Inflammation, as Judged on Clinical Criteria, According to Standard Methods (Reduction of Anterior Chamber Cellular Activity and/or Chorioretinal Infiltrates and/or Retinal Vasculitis); Reduction in Cystoid Macular Edema
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.